The World Health Organization on Tuesday (June 1) approved the Sinovac vaccine for emergency use. This is the second Chinese vaccine “green light” by WHO.
The United Nations health agency on June 1 officially recognized the 2-dose vaccine of Sinovac (China).
“I am pleased to announce that Sinovac’s CoronaVac vaccine has been placed on the WHO emergency use list after being assessed as safe, effective and of guaranteed quality,” said WHO Director Tedros Adhanom Ghebreyesus. in the press conference.
He added that CoronaVac’s easy storage makes it well-suited to many regions of the world.
“Now it is important to quickly get these life-saving tools to those who need them,” said WHO Director-General.
The agency said in a statement: “WHO recommends this vaccine be given to adults 18 years of age and older as two doses with a two- to four-week interval between each dose.”
“Vaccine efficacy studies showed that the vaccine prevented symptomatic disease in 51% of those vaccinated and prevented severe progression of COVID-19 requiring hospitalization in 100%. number of people studied,” said WHO.
Sinovac vaccine contains an inactivated form of corona virus that cannot cause disease. It also has a substance that enhances the immune response to the vaccine.
When injected, the immune system identifies the inactivated virus as foreign and produces antibodies against it, which will then recognize the active virus and defend the body against it.
Very few people over the age of 60 have participated in a clinical trial with Sinovac’s vaccine.
However, WHO says there should be no upper age limit for vaccines.
The Sinovac vaccine has been used in 22 territories around the world, according to AFP data.
Apart from China, countries using Sinovac include Chile, Brazil, Indonesia, Mexico, Thailand and Turkey.
However, the effectiveness of Chinese vaccines has been questioned by many experts, especially when there have been numerous reports of dozens of deaths in Hong Kong and the mainland after vaccination.
>> Hong Kong: 3 people died in 9 days after receiving the Chinese vaccine
Being approved on the WHO’s emergency use list (EUL) means that there is WHO assurance that the vaccine has met international standards.
Last month, Sinopharm became the first Chinese vaccine approved by the WHO.
WHO has also previously approved vaccines made by Pfizer/BioNTech, Moderna, Johnson & Johnson and AstraZeneca made in India, South Korea and the EU.
The WHO list paves the way for countries worldwide to approve and import vaccines for rapid distribution, especially those that do not have their own international standards governing body.
This also means that Sinovac will be included in WHO’s global COVAX vaccine sharing facility, which is an initiative to equitably deliver vaccines to less developed countries around the world.
Currently only AstraZeneca and a small number of Pfizer vaccines are being distributed through this program.
“The world desperately needs a COVID-19 vaccine to tackle inequality of access globally,” said Mariangela Simao, WHO assistant director-general.
“We urge manufacturers to join the COVAX facility, sharing their know-how and data to contribute to pandemic control.”